Related references
Note: Only part of the references are listed.Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival
Peter J. Mazzaglia et al.
SURGERY (2007)
Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors
Alexander S. Ho et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2007)
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours
F. Marrache et al.
BRITISH JOURNAL OF CANCER (2007)
Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu- DOTA0, Tyr3] octreotide:: which peptide is preferable for PRRT?
J. P. Esser et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors
Thomas E. Clancy et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2006)
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas
M. P. Ducreux et al.
ONCOLOGY (2006)
Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic)
Ola Nilsson et al.
NEUROENDOCRINOLOGY (2006)
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors - Variables affecting response rates and survival
S Gupta et al.
CANCER (2005)
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
WJ Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Incidence and management of malignant digestive endocrine tumours in a well defined French population
C Lepage et al.
GUT (2004)
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
MA Kouvaraki et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study
L Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas
QD Chu et al.
ANNALS OF SURGICAL ONCOLOGY (2002)
Epidemiology and survival in patients with carcinoid disease in the Netherlands - An epidemiological study with 2391 patients
PFHJ Quaedvlieg et al.
ANNALS OF ONCOLOGY (2001)
[177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:: A clinical phase II study
C Waldherr et al.
ANNALS OF ONCOLOGY (2001)
Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97
F Levi et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
